Dr. Michael Scharf, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 538
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: New York Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
PA license MD042791L · NJ license 25MA06300700
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Thomas Jefferson University Hospital Philadelphia, PA
- Jefferson Abington Hospital Abington, PA
Medical groups
- Jefferson University Physicians (1,531 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 538
- Services billed
- 1,505
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Test to examine how well the lungs exchange gases | 228 | 226 |
| Test to determine lung volumes using sensors | 209 | 207 |
| Test to measure expiratory airflow and volume | 204 | 198 |
| Established patient office or other outpatient visit, 30-39 minutes | 165 | 115 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 153 | 152 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 104 | 51 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 70 | 32 |
| Test for exercise-induced lung stress | 56 | 48 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 49 | 46 |
| Established patient office or other outpatient visit, 20-29 minutes | 40 | 39 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tadalafil | 193 |
| Opsumit (macitentan) | 181 |
| Ambrisentan | 113 |
| Tyvaso Dpi (treprostinil) | 104 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Philadelphia, PA | 102 |
| Uptravi (selexipag) | 100 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Philadelphia, PA | 85 |
| Prednisone Other prescribers in Philadelphia, PA | 77 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Philadelphia, PA | 75 |
| Sildenafil Citrate Other prescribers in Philadelphia, PA | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $116 in total to this clinician.
| Merck Sharp & Dohme LLC | $77.10 |
|---|---|
| GlaxoSmithKline, LLC. | $38.71 |
| Education | $77.10 |
|---|---|
| Food and Beverage | $38.71 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 24, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Jan 28, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $25,109 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies wi…
Janssen Research & Development, LLC - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.